Senseonics launches Eversense 365 in Europe, debuting the first year-long CGM system as it expands into key markets and ...

Key Takeaways Continuous glucose monitors (GCM) can help type 2 diabetes patients manage blood sugarPatients had better blood ...

Senseonics has launched Eversense 365, the world’s first year-long implantable continuous glucose monitor, in Europe, marking a leap in device longevity and ease of use. The debut comes amid growing ...

Tandem Diabetes Care issued an urgent medical device correction to upgrade the software of its Tandem Mobi insulin pumps that ...

Diabetes, especially type 1 and insulin-treated type 2, is significantly associated with an increased risk for all-cause ...

In terms of stakeholders revenue share in 2022, the Mobile Operators and Device Vendors segments represented more than ...

A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving ...

Senseonics Holdings has launched its Eversense 365 CGM system in Europe, following CE Mark approval in January.

FDA clears Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy for people with type ...

The FDA has cleared Tandem’s Control-IQ technology as the first ever AID specifically for use in pregnancies complicated by type 1 diabetes.